AI Science Tracker
EN

Chengdu University of Traditional Chinese Medicine

2 discoveries from 2024 to 2026

Discoveries

Trajectory analysis of sleep disorders and anxiety-depression in female breast cancer patients undergoing chemotherapy: based on group-based Multi-Trajectory Model and machine learning.

Source check: Source checked. Not independent scientific confirmation.

Finding: primary Methods/Results document the AI-enabled result, evaluation and bounded interpretation. Publication venue was not available in the checked primary metadata. It does not establish generalization beyond the reported setting or prospective real-world benefit.

Technology: LASSO selected predictors for seven compared machine-learning models that classified symptom-trajectory groups in a prospective chemotherapy cohort; the group-based multi-trajectory model itself was statistical.

Publication: Publication status unspecified in annotation · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
LASSO selected predictors for seven compared machine-learning models that classified symptom-trajectory groups in a prospective chemotherapy cohort; the group-based multi-trajectory model itself was statistical.
Test and result
In 150 breast-cancer patients followed through four chemotherapy cycles, the group-based multi-trajectory model identified stable (74.7%) and deteriorating (25.3%) sleep/anxiety-depression symptom groups. Seven machine-learning models assessed factors associated with the deteriorating group; the selected Naive Bayes model had test AUC 0.863, accuracy 0.839 and Brier score 0.132. Risk-factor associations are not causal.
Limitation / still unknown
Independent replication and prospective real-world benefit are not established in the reviewed study.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1186/s12911-026-03672-1

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Machine learning helps identify a Beclin 2-Ubiquilin 1 interaction in breast-cancer cells

Source check: Source checked. Not independent scientific confirmation.

Finding: Classical machine-learning classifiers predicted autophagy-related protein interactions, which researchers intersected with immunoprecipitation-mass-spectrometry results to select candidates in triple-negative breast-cancer cells. Co-immunoprecipitation supported the Beclin 2-Ubiquilin 1 interaction, and cell experiments linked Beclin 2 overexpression to increased Ubiquilin 1, autophagy and reduced proliferation and migration. Despite the title, the reported classifiers are Naive Bayes, decision trees and k-nearest neighbors; the results do not establish clinical benefit.

Technology: Naive Bayes; decision tree; k-nearest neighbors

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Naive Bayes, decision-tree and k-nearest-neighbor classifiers predicted protein interactions; predictions were intersected with experimentally detected Beclin 2-associated proteins before targeted validation.
Test and result
Co-immunoprecipitation supported the predicted Beclin 2-Ubiquilin 1 interaction; subsequent MDA-MB-231 cell assays examined autophagy, proliferation and migration.
Limitation / still unknown
The represented result is from cell experiments, not clinical treatment. Predicted interaction counts are not experimentally confirmed interaction counts.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.32604/or.2024.055921 · https://pmc.ncbi.nlm.nih.gov/articles/PMC11671618/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary full article Methods, result-specific experiments, discussion, affiliations and journal publication metadata; no independent replication performed..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.